News
PPCB
1.490
+1.36%
0.020
Weekly Report: what happened at PPCB last week (0615-0619)?
Weekly Report · 3d ago
Propanc CEO visits European manufacturer ahead of drug production plan
TipRanks · 06/16 13:41
Propanc Biopharma CEO tours European CDMO GMP facility ahead of PRP production for Phase 1b study
PUBT · 06/16 12:45
10 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 06/15 12:05
Weekly Report: what happened at PPCB last week (0608-0612)?
Weekly Report · 06/15 10:35
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 06/12 17:05
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 06/12 12:05
Why Friedman Industries Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Benzinga · 06/12 09:29
BUZZ-U.S. STOCKS ON THE MOVE-Intel, Victoria's Secret, Super Micro
Reuters · 06/11 17:41
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 06/11 17:05
BUZZ-U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Oracle
Reuters · 06/11 15:44
ShareStructure.io Announces Investor Education Platform on Public Company Financing Activity.
TipRanks · 06/11 14:00
Dow Jumps Over 250 Points; US Initial Jobless Claims Rise
Benzinga · 06/11 13:55
Propanc Biopharma announces $5M share repurchase program
TipRanks · 06/11 13:14
Propanc Biopharma authorizes $5M share buyback program; shares surge
Seeking Alpha · 06/11 12:56
Propanc Biopharma Announces $5M Common Stock Buyback Plan
Benzinga · 06/11 12:34
PROPANC BIOPHARMA AUTHORIZES $5.0 MILLION SHARE REPURCHASE PROGRAM
Reuters · 06/11 12:30
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 06/11 12:05
Weekly Report: what happened at PPCB last week (0601-0605)?
Weekly Report · 06/08 10:30
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 06/04 12:05
More
Webull provides a variety of real-time PPCB stock news. You can receive the latest news about Propanc Bio through multiple platforms. This information may help you make smarter investment decisions.
About PPCB
Propanc Biopharma, Inc. is an Australia-based biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.